Glenmark gets FDA's blessing for generic Aubagio
Glenmark Pharmaceuticals has received the Food and Drug Administration's approval for teriflunomide tablets in 7-mg and 14-mg dosage strengths.
The product is a generic version of Sanofi-Aventis’ Aubagio tablets 7 mg and 14 mg. It is used to treat relapsing forms of multiple sclerosis.
Aubagio tablets 7 mg and 14 mg had a market value of approximately $1.6 billion for the 12-month period ending September 2018, according to IQVIA.
The product is a generic version of Sanofi-Aventis’ Aubagio tablets 7 mg and 14 mg. It is used to treat relapsing forms of multiple sclerosis.
Aubagio tablets 7 mg and 14 mg had a market value of approximately $1.6 billion for the 12-month period ending September 2018, according to IQVIA.